INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia

I Dzneladze, R He, JF Woolley, MH Son, MH Sharobim, SA Greenberg, M Gabra, C Langlois, A Rashid, A Hakem, N Ibrahimova, A Arruda, Bob Löwenberg, Peter Valk, MD Minden, L Salmena

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Scopus)


In this study, we investigated the role of inositol polyphosphate-4-phosphatase, type-II (INPP4B) in acute myeloid leukemia (AML). We observed that AML patients with high levels of INPP4B (INPP4B(high)) had poor response to induction therapy, shorter event-free survival and shorter overall survival. Multivariate analyses demonstrated that INPP4B(high) was an independent predictor of poor prognosis, significantly improving current predictive models, where it outperformed conventional biomarkers including FLT3-ITD and NPM1. Furthermore, INPP4B(high) effectively segregated relative risk in AML patients with normal cytogenetics. The role of INPP4B on the biology of leukemic cells was assessed in vitro. Overexpression of INPP4B in AML cell lines enhanced colony formation potential, recapitulated the chemotherapy resistance observed in AML patients and promoted proliferation in a phosphatase-dependent, and Akt-independent manner. These findings reveal that INPP4B(high) has an unexpected role consistent with oncogenesis in AML, in contrast to its previously reported tumor-suppressive role in epithelial cancers. Overall, we propose that INPP4B is a novel prognostic biomarker in AML that has potential to be translated into clinical practice both as a disease marker and therapeutic target.
Original languageUndefined/Unknown
Pages (from-to)1485-1495
Number of pages11
Issue number7
Publication statusPublished - 2015

Research programs

  • EMC MM-02-41-03

Cite this